Renal side effects of adefovir in hepatitis B virus-(HBV) positive kidney allograft recipients

Clinical Nephrology

Volumn 71, Issue 1, 2009, Pages 36-42

  Kamar, N ^a,c   Huart, A ^a   Tack, I ^a   Alric, L ^b   Izopet, J ^b,c   Rostaing, L ^a,c,d  

^a CHU RANGUEIL   (France)

^b CHU PURPAN   (France)

^c INSERM   (France)

^d Service de Néphrologie Transplantation d'Organes   (France)

Author keywords

Adefovir; Bicarbonaturia; Creatinine; HBV DNA; Hypophosphatemia; Kidney transplantation

Indexed keywords

ADEFOVIR; ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; CALCINEURIN INHIBITOR; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B(E) ANTIBODY; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHATE; PHOSPHORUS; RAPAMYCIN; STEROID; VIRUS DNA; ADENINE; ANTIVIRUS AGENT; DRUG DERIVATIVE; PHOSPHONIC ACID DERIVATIVE;

ADULT; AGED; ARTICLE; CHLORIDE BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; KIDNEY ALLOGRAFT; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY PROXIMAL TUBULE; KIDNEY TRANSPLANTATION; KIDNEY TUBULE; LOW DRUG DOSE; MAGNESIUM BLOOD LEVEL; MAGNESIUM URINE LEVEL; MALE; NONHUMAN; PHOSPHATE BLOOD LEVEL; PHOSPHATURIA; POTASSIUM BLOOD LEVEL; PROTEINURIA; RECIPIENT; SIDE EFFECT; URIC ACID BLOOD LEVEL; URINARY EXCRETION; URINE PH; VIRUS MUTANT; ACID BASE BALANCE; ANTIVIRAL RESISTANCE; COHORT ANALYSIS; DOSE RESPONSE; DRUG EFFECT; KIDNEY; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; RETROSPECTIVE STUDY;

ACID-BASE EQUILIBRIUM; ADENINE; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, VIRAL; FEMALE; GLOMERULAR FILTRATION RATE; HEPATITIS B, CHRONIC; HUMANS; KIDNEY; KIDNEY TRANSPLANTATION; LAMIVUDINE; MALE; MIDDLE AGED; PHOSPHONIC ACIDS; RETROSPECTIVE STUDIES;

EID: 63249095067     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.5414/CNP71036     Document Type: Article

References (30)

1. Ader JL, Tack I, Lloveras JJ et al. Renal functional reserve in cyclosporin-treated recipients of kidney transplant. Kidney Int. 1994; 45: 1657-1667.
2. ADHOC International Steering Committee. A randomized placebo-controlled trial of adefovir dipivoxil in advanced HIV infection: the ADHOC trial. HIV Med 2002, 3: 229-238.
3. Ahn HJ, Kim MS, Kim YS et al. Clinical outcome of renal transplantation in patients with positive pre-transplant hepatitis B surface antigen. J Med Virol. 2007; 79: 1655-1663.
4. Baid-Agrawal S, Pascual M, Moradpour D et al. Hepatitis C virus infection in haemodialysis and kidney transplant patients. Rev Med Virol. 2007; Epub ahead of print.
5. Baker R. Kidney dysfunction: a safety update on adefovir (preveon). BETA. 1998; July: 9-10.
6. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996; 24: 289-293.
7. Brind AM, Bennett MK, Bassendine MF. Nucleoside analogue therapy in fibrosing cholestatic hepatitis - a case report in an HBsAg positive renal transplant recipient. Liver. 1998; 18: 134-139.
8. Cieciura T, Urbanowicz A, Perkowka-Ptasinska A et al. Tubular and glomerular proteinuria in diagnosing chronic allograft nephropathy with relevance to the degree of urinary albumin excretion. Transplant Proc. 2005; 37: 987-990.
9. Dando T, Plosker G. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 2003; 63: 2215-2234.
10. De Silva HJ, Dassanayake AS, Manamperi A, de Silva AP. Treatment of lamivudine-resistant hepatitis B infection in post-renal transplant patients with adefovir dipivoxil: preliminary results. Transplant Proc. 2006; 38: 3118-3120.
11. Delaney WE 4th. Progress in the treatment of chronic hepatitis B: long-term experience with adefovir dipivoxil. J Antimicrob Chemother. 2007; 59: 827-832.
12. Durlik M, Gaciong Z, Rowinska D et al. Long-term results of treatment of chronic hepatitis B, C and D with interferon-alpha in renal allograft recipients. Transplant Int. 1998; 11 Suppl 1: S135-S139.
13. Fabrizi F, Martin P, Lunghi G, Ponticelli C. Natural history of HBV in dialysis population. G Ital Nefrol 2004; 21: 21-28.
14. Fisher EJ, Chaloner K, Cohn DL et al. The safety and efficacy of adefovir dipivoxil in patients with advanced HIV disease: a randomized, placebo-controlled trial. AIDS. 2001; 15: 1695-1700.
15. Fontaine H, Thiers V, Chrétien Y et al. HBV genotypic resistance to lamivudine in kidney recipients and hemodialyzed patients. Transplantation. 2000; 69: 2090-2094.
16. Fontaine H, Vallet-Pichard A, Chaix ML et al. Efficacy and safety of adefovir dipivoxil in kidney recipients, hemodialysis patients, and patients with renal insufficiency. Transplantation. 2005; 80: 1086-1092.
17. Fornairon S, Pol S, Legendre C et al. The long-term virologic and pathologic impact of renal transplantation on chronic hepatitis B virus infection. Transplantation. 1996; 62: 297-299.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology. 2006; 131: 1743-1751.
19. Harnett JD, Parfrey PS, Kennedy M et al. The long-term outcome of hepatitis B infection in hemodialysis patients. Am J Kidney Dis. 1988; 11: 210-213.
20. Harnett JD, Zeldis JB, Parfrey PS et al. Hepatitis B disease in dialysis and transplant patients. Further epidemiologic and serologic studies. Transplantation. 1987; 44: 369-376.
21. Hung YB, Liang JT, Chu JS, Chen KM, Lee CS. Fulminant hepatic failure in a renal transplant recipient with positive hepatitis B surface antigens: a case report of fibrosing cholestatic hepatitis. Hepatogastroenterology. 1995; 42: 913-918.
22. Kahn J, Lagakos S, Wulfsohn M et al. Efficacy and safety of adefovir dipivoxil with antiretroviral therapy: a randomized controlled trial. JAMA. 1999; 282: 2305-2312.
23. Kamar N, Allard J, Ribes D et al. Assessment of glomerular and tubular functions in renal transplant patients receiving cyclosporine A in combination with either sirolimus or everolimus. Clin Nephrol. 2005; 63: 80-86.
24. Kamar N, Sandres-Sauné K, Ribes D et al. Effects of long-term lamivudine therapy in renal-transplant patients. J Clin Virol. 2004; 31: 298-303.
25. Mariat C, Alamartine E, Afiani A et al. Predicting glomerular filtration rate in kidney transplantation: are the K/DOQI guidelines applicable? Am J Transplant 2005; 5: 2698-703.
26. Mathurin P, Mouquet C, Poynard T et al. Impact of hepatitis B and C on kidney transplantation outcome. Hepatology 1999; 29: 257-263.
27. Myerson RM, Pastor BH. The Fanconi syndrome and its clinical variants. Am J Med Sci. 1954; 228: 378-387.
28. Servais A, Lechat P, Zahr N, Urien S et al. Tubular transporters OAT1 and MRP2 and clearance of adefovir. Nephrol Ther 2005 1: 296-300.
29. Tanaka S, Yoshiba M, Iino S et al. Acommon-source outbreak of fulminant hepatitis B in hemodialysis patients induced by precore mutant. Kidney Int. 1995; 48: 1972-1978.
30. Tanji N, Tanji K, Kambham N et al. Adefovir nephrotoxicity: possible role of mitochondrial DNA depletion. Hum Pathol. 2001; 32: 734-740.